Yasmin Kit
Product Images NDC 50419-402

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Yasmin (NDC 50419-402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formulas (425be71d 812e 4a54 8dea Bb27eb6b4ecf 03)

Drospirenone and Ethinyl estradiol are two types of hormones used in combination to make birth control pills. They work together to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and altering the lining of the uterus.*

FDA Label Image

Pregnancy Diagram (425be71d 812e 4a54 8dea Bb27eb6b4ecf 04)

This text describes different contraceptive methods and their effectiveness. It lists the different levels of pregnancies per 100 women using various methods, from less than 1 pregnancy to over 85 pregnancies. It also mentions the different types of birth control, including injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring, condoms, diaphragm, spermicide, withdrawal, and no birth control. It suggests avoiding sex during the most fertile days of the monthly cycle and highlights the importance of contraception.*

FDA Label Image

Pill Pack Image (425be71d 812e 4a54 8dea Bb27eb6b4ecf 05)

FDA Label Image

Blood Clot Diagram (425be71d 812e 4a54 8dea Bb27eb6b4ecf 06)

This text appears to be a table that shows numerical ranges of blood clotting incidents among women with different conditions such as being pregnant, postpartum or not on COC (contraceptive pill). The table lists the number of women with blood clots per 10,000 women years. The footnote mentions that pregnancy data is based on actual duration and the given rate is calculated based on model assumption.*

FDA Label Image

Trade Carton (425be71d 812e 4a54 8dea Bb27eb6b4ecf 07)

FDA Label Image

50419 0402 01 Splimage30 B8195c0a

FDA Label Image

50419 0402 01 Splimage30 Bb195dea

FDA Label Image

Image 01

FDA Label Image

Image 02

This text provides information on the ranges of blood clot occurrence in different groups of women categorized based on their pregnancy status and contraceptive use. It includes a chart showing the number of women with a blood clot per 10,000 women-years in these groups. The data for pregnancy in the chart is based on the actual duration of pregnancy in reference studies, considering a model assumption that pregnancy duration is nine months.*

FDA Label Image

Image 03

This text provides a list of relevant studies conducted on the risk of breast cancer associated with combined oral contraceptives. The studies include NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, Nurses' Health Study Il, Oxford Family Planning Study, and Danish Sex Hormone Register Study. The text also presents effect estimates in the form of OR, RR, and HR for different comparisons.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.